...
首页> 外文期刊>Journal of vector borne diseases. >Substandard artemisinin-based antimalarial medicines in licensed retail pharmaceutical outlets in ghana
【24h】

Substandard artemisinin-based antimalarial medicines in licensed retail pharmaceutical outlets in ghana

机译:在加纳的特许零售药店中,基于青蒿素的抗疟药达不到标准

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background & objectives: The artemisinin-based antimalarial medicines are first line medicines in the treatment of severe and uncomplicated falciparum malaria. Numerous brands of these medicines manufactured in various countries are available in the Ghanaian market. The study was aimed at evaluating the authenticity and quality of selected brands of artemisinin-based antimalarial medicines marketed in Ghana. Methods: In all, 14 artemisinin-based antimalarial medicines were purchased from pharmacies (P) and licensed chemical shops (LCSs) in the Kumasi metropolis, Ghana. Simple field tests based on colorimetry and thin layer chromatography were employed in determining the authenticity of the samples. Important quality assessment tests, namely uniformity of mass, crushing strength, disintegration time, and the percentage content of active pharmaceutical ingredients (APIs) were determined. Results: All the brands tested contained the stipulated APIs. Artesunate tablet AT2 failed the uniformity of mass test while artesunate tablets AT3 & AT4 as well as amodiaquine tablets AM4 & AM6 failed the crushing strength test. All the six artemether-lumefantrine tablet brands passed the uniformity of mass, crushing strength and disintegration tests. Only artemether-lumefantrine tablet brand AL1 contained the correct amount of the drugs. The other 13 artemisinin products contained either a lower (underdose) or higher (overdose) amount of the specified drug. Artesunate monotherapy tablets were readily available in pharmacies and licensed chemical shops. Interpretation & conclusion: All the artemisinin-based medicines tested (except AL1) were of substandard quality. The results demonstrate the need for continuous monitoring and evaluation of the quality of artemisininbased antimalarials in the Ghanaian market. Also, the practice of artemisinin antimalarial monotherapy is prevalent in Ghana. Determined efforts should, therefore, be made to eradicate the practice to prevent the development of resistance to the artemisinins.
机译:背景与目的:基于青蒿素的抗疟药物是治疗严重且不复杂的恶性疟疾的一线药物。加纳市场上有许多在不同国家生产的这些药物的品牌。这项研究旨在评估在加纳销售的精选青蒿素类抗疟药品牌的真实性和质量。方法:从加纳库玛西大都会的药房(P)和许可的化学商店(LCS)购买了14种基于青蒿素的抗疟药。基于比色法和薄层色谱法的简单现场测试用于确定样品的真实性。确定了重要的质量评估测试,即质量均匀性,抗碎强度,崩解时间和活性药物成分(API)的百分比含量。结果:所有测试的品牌均包含规定的API。青蒿琥酯片剂AT2未通过质量测试的均一性,而青蒿琥酯片剂AT3和AT4以及阿莫二喹片剂AM4和AM6未通过抗碎强度测试。六个蒿甲醚-荧光粉片剂品牌均通过了质量均匀性,抗碎强度和崩解测试。只有蒿甲醚-黄麻素片剂品牌AL1含有正确数量的药物。其他13种青蒿素产品所含指定药物的量较少(不足)或较高(过量)。青蒿琥酯单药片剂可在药房和有执照的化学商店中买到。解释与结论:测试的所有基于青蒿素的药物(AL1除外)质量均不合格。结果表明,需要对加纳市场中基于青蒿素的抗疟药质量进行持续监测和评估。同样,在加纳,青蒿素抗疟单一疗法的实践十分普遍。因此,应做出坚定的努力以根除这种做法,以防止对青蒿素产生抗药性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号